Page contentsPage contents Key facts Decision Key facts Active substance tucatinib Therapeutic area Oncology Decision number P/0036/2018 PIP number EMEA-002242-PIP01-17 Pharmaceutical form(s) Tablet Condition(s) / indication(s) Treatment of breast malignant neoplasms Route(s) of administration Oral use Contact for public enquiries Cascadian Therapeutics Luxembourg S.A.R.L. Tel. +1 2068012100E-mail: HER2CLIMBinquiries@cascadianrx.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 31/01/2018 Compliance check done No Decision P/0036/2018: EMA decision of 30 January 2018 on the granting of a product specific waiver for tucatinib (EMEA-002242-PIP01-17)Reference Number: EMA/848797/2017 English (EN) (70.05 KB - PDF)First published: 18/04/2018 Last updated: 18/04/2018 View Share this page